Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „zoledronic“
Suchtreffer
Begriffe & Kennungen
Aclasta · 4.5 · No interaction studies with other medicinal products have been performed. Zoledronic acid is not systemically
Eintrag öffnenAclasta · 4.5 · Zoledronic acid is eliminated by renal excretion. Caution is indicated when zoledronic acid is administered in
Eintrag öffnenAclasta · 4.8 · 8 Class effects Renal impairment Zoledronic acid has been associated with renal impairment manifested as deter
Eintrag öffnenDegevma · 4.8 · A higher incidence of ONJ among patients treated with denosumab compared to zoledronic acid has been observed
Eintrag öffnenDegevma · 4.8 · Hypocalcaemia A higher incidence of hypocalcaemia among patients treated with denosumab compared to zoledronic
Eintrag öffnenDegevma · 4.8 · The cumulative incidence at one year was 1.1 % for denosumab and 0.6 % for zoledronic acid, respectively.
Eintrag öffnenOsenvelt · 4.8 · 9 1.0 - 51.7) and 33/3688 (0.9%) of patients treated with zoledronic acid (median exposure of 12.9 months; ran
Eintrag öffnenOsenvelt · 4.8 · A higher incidence of ONJ among patients treated with denosumab compared to zoledronic acid has been observed
Eintrag öffnenOsenvelt · 4.8 · Hypocalcaemia A higher incidence of hypocalcaemia among patients treated with denosumab compared to zoledronic
Eintrag öffnenOsenvelt · 4.8 · The cumulative incidence at one year was 1.1% for denosumab and 0.6 % for zoledronic acid, respectively.
Eintrag öffnenVevzuo · 4.8 · 7 treated with zoledronic acid.
Eintrag öffnenVevzuo · 4.8 · A higher incidence of ONJ among patients treated with denosumab compared to zoledronic acid has been observed
Eintrag öffnenVevzuo · 4.8 · Hypocalcaemia A higher incidence of hypocalcaemia among patients treated with denosumab compared to zoledronic
Eintrag öffnenVevzuo · 4.8 · The cumulative incidence at one year was 1.1 % for denosumab and 0.6 % for zoledronic acid, respectively.
Eintrag öffnenXgeva · 4.8 · A higher incidence of ONJ among patients treated with denosumab compared to zoledronic acid has been observed
Eintrag öffnenXgeva · 4.8 · Hypocalcaemia A higher incidence of hypocalcaemia among patients treated with denosumab compared to zoledronic
Eintrag öffnenXgeva · 4.8 · The cumulative incidence at one year was 1.1% for denosumab and 0.6% for zoledronic acid, respectively.
Eintrag öffnenZoledronic acid Mylan
Eintrag öffnenZoledronic acid Mylan · 4.1 Therapeutic indications · 1
Eintrag öffnenZoledronic acid Mylan · 4.3 Contraindications · 1
Eintrag öffnen